Literature DB >> 25826240

Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.

Zeev Blumenfeld1, Ayelet Evron.   

Abstract

INTRODUCTION: The late effects of cancer treatment have recently gained a worldwide ubiquitous interest among reproductive endocrinologists, oncologists, and all health care providers. Despite many publications on this subject, there are many equivocal issues necessitating summary. The case for and against using GnRH-agonist for fertility preservation is summarized with the rationale that preventing ovarian failure may be better than treating it. AREAS COVERED: We searched Medline in the last 10 years using terms: 'fertility preservation', 'female chemotherapy', 'Gonadotropin-releasing hormone (GnRH) analogues', 'GnRH agonists' 'gonadotoxicity', and 'cancer treatment'. We included mainly publications from the past 7 years, but did not exclude previous, commonly referenced publications. Here, we summarize the various methods available for fertility preservation and minimizing chemotherapy induced gonadotoxicity. EXPERT OPINION: Until now, 20 studies (15 retrospective and 5 randomized controlled trial) have reported on 2038 patients treated with GnRH-a in parallel to chemotherapy, showing a significant decrease in premature ovarian failure (POF) rate in survivors versus 8 studies reporting on 509 patients, with negative results. Patients treated with GnRH-a in parallel to chemotherapy preserved their cyclic ovarian function in 91% of cases as compared to 41% of controls, with a pregnancy rate of 19 - 71% in the treated patients. Furthermore, over 10 recent meta-analyses have concluded that GnRH-a are beneficial and may decrease the risk of POF in survivors. Because most of the methods involving ovarian or egg cryopreservation are not yet clinically established and unequivocally successful, these young patients deserve to be informed with all the various modalities to minimize gonadal damage and preserve ovarian function and future fertility. Combining the various modalities for a specific patient may increase the odds of preservation of future fertility.

Entities:  

Keywords:  fertility preservation; gonadotoxicity; gonadotropin-releasing hormone agonist; premature ovarian failure

Mesh:

Substances:

Year:  2015        PMID: 25826240     DOI: 10.1517/14656566.2015.1031654

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  12 in total

1.  Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.

Authors:  R Phelan; E Mann; C Napurski; T E DeFor; A Petryk; W P Miller; J E Wagner; M R Verneris; A R Smith
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

2.  A Combination of a GnRH Antagonist and Agonist for Fertility Preservation in an Adolescent Female Murine Model.

Authors:  Jennifer Flora Knudtson; Marlen Tellez Santos; Courtney M Failor; Peter A Binkley; Jacob P Venesky; Rajeshwar R Tekmal; Randal D Robinson; Robert S Schenken
Journal:  Reprod Sci       Date:  2016-12-14       Impact factor: 3.060

Review 3.  Infertility - Prevention and Management.

Authors:  Emily C Somers; Wendy Marder
Journal:  Rheum Dis Clin North Am       Date:  2017-03-14       Impact factor: 2.670

4.  Case report: term birth after fertility-sparing treatments for stage IB1 small cell neuroendocrine carcinoma of the cervix.

Authors:  Pei-Ying Wu; Ya-Min Cheng; Geok Huey New; Cheng-Yang Chou; Chun-Ting Chiang; Hung-Wen Tsai; Yu-Fang Huang
Journal:  BMC Womens Health       Date:  2017-07-28       Impact factor: 2.809

5.  Development of Ovarian Tissue Autograft to Restore Ovarian Function: Protocol for a French Multicenter Cohort Study.

Authors:  Jean-Baptiste Pretalli; Sophie Frontczak Franck; Lionel Pazart; Christophe Roux; Clotilde Amiot
Journal:  JMIR Res Protoc       Date:  2019-09-30

Review 6.  Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy.

Authors:  Zeev Blumenfeld
Journal:  Clin Med Insights Reprod Health       Date:  2019-08-21

7.  Primordial Follicle Transplantation within Designer Biomaterial Grafts Produce Live Births in a Mouse Infertility Model.

Authors:  E Kniazeva; A N Hardy; S A Boukaidi; T K Woodruff; J S Jeruss; L D Shea
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

8.  Pure Immature Teratoma of the Ovary in Adults: Thirty-Year Experience of a Single Tertiary Care Center.

Authors:  Ahmad Bakr Alwazzan; Shaundra Popowich; Erin Dean; Christine Robinson; Robert Lotocki; Alon D Altman
Journal:  Int J Gynecol Cancer       Date:  2015-11       Impact factor: 3.437

Review 9.  Fertility Preservation in Cancer Patients: In Vivo and In Vitro Options.

Authors:  Rouhollah Fathi; Mojtaba Rezazadeh Valojerdi; Bita Ebrahimi; Farideh Eivazkhani; Mahzad Akbarpour; Leila Sadat Tahaei; Naeimeh Sadat Abtahi
Journal:  Cell J       Date:  2017-02-22       Impact factor: 2.479

10.  Laparoscopic Ovarian Transposition and Ovariopexy for Fertility Preservation in Patients Treated with Pelvic Radiotherapy with or without Chemotherapy.

Authors:  L Turkgeldi; A Cutner; E Turkgeldi; A Al Chami; A Cassoni; N Macdonald; T Mould; A Nichol; A Olaitan; E Saridogan
Journal:  Facts Views Vis Obgyn       Date:  2019-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.